Lia GoreProgram Leader, Experimental Therapeutics Program Center for Cancer and Blood Disorders Children’s Hopsital Colorado
Tomoyuki IgawaGroup Manager, Discovery Research Chugai Pharmaceutical Co.,Ltd.
Horst LindhoferCEO Trion Pharma
Sean McKennaDirector and US Head of Protein Engineering and Antibody Technologies EMD Serono
The Bispecific Antibody Summit represents an outstanding opportunity for you to learn the lessons of the most successful drug developers in the field. For just a few days out of the office, you’ll save months and potentially years of development heartache. You’ll leave armed with dozens of new ideas and contacts that you can start using right away. And crucially, you’ll find new, innovative and cost effective ways of overcoming troublesome preclinical and clinical development challenges.
Here are just a few of the topics where you’ll take away critical lessons:
This is a very different type of bispecifics meeting, focussing on delivering knowledge, contacts and information that will make a noticeable difference to your performance.
Here’s how that’s achieved:
The audience is 100% focussed on bispecifics, and consists of over 75% drug developers. That’s fairly unique for an antibody-related conference. Meaning you have an opportunity to meet with, and learn from, people who spend all of their professional time overcoming bispecific challenges.
Speakers and panellists are instructed to focus on information relevant to your business. Sure, there’s coverage of format engineering. But you won’t find a speaker who isn’t willing to offer development advice that you can use when you get back to the lab. Unlike other bispecifics conferences, the focus is on getting to the root of the problems, and solving them. Expect lengthy, interactive discussion throughout the two main conference days
Have a specific problem? Get it solved here. Through speed networking, panel discussions, interactive Q&A, MasterMind groups and informal networking, you’ll have lots of opportunity to ask the difficult questions that matter to your business. And if you still didn’t get the answer, don’t worry. Just write it on the dedicated Questions Board, and we’ll see it gets addressed in the closing panel discussion at the end of day two.
Speakers are invited from referrals only. To ensure the speakers truly have something valuable to say, we only invite people who have been nominated by their peers. Speakers are selected for their pioneering work, innovative approaches and a willingness to challenge existing thinking.
"The best conference in the bispecific field"
George Wang, Group Head, Bayer
"A very good conference, with a good diversity of talks" Laurence Fayadat-Dilman, Senior Principal Scientist, Merck & Co
"Provides an excellent overview of the field, and excellent networking opportunities" Andreas Menrad, CSO, Ablynx
"A well organized conference on bispecifics covering all areas of drug discovery and development" Surendran Rajendran, Senior Research Investigator, Bristol-Myers Squibb
"Fantastic speakers and very focussed!" David Poon, Associate Director, Business Development, Zymeworks
"A good opportunity to improve my fundamental understanding of the bispecifics field" Shigeo Hirasawa, Senior Researcher, Ajimoto Co.
"An excellent opportunity to learn about the latest developments in the bispecific antibody field" Rajkumar Ganesan, Principal Scientist, Boehringer Ingelheim
"Very informative, educational and enlightening conference for scientists who have different levels of experiences in bispecifics" Xinwei Wang, Associate Scientist II, MedImmune
"Provides an excellent overview of the bispecifics field, and brings people of the field together for stimulating discussions and future research" Florian Schelter, Scientist, Roche
"Great speakers, great networking, great and stimulating discussions!" Ercole Rao, Group Leader, Sanofi
"A highly interactive conference with excellent presentations and exciting data" Hilde Reverts, Senior Research Fellow, Ablynx
"Technical experts in the field of bispecifics coming together to discuss their successes" Leah Helvering, Senior Scientist, Eli Lilly